Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Sales (2016 - 2025)

Historic Return on Sales for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 2.1%.

  • ImmunityBio's Return on Sales rose 119500.0% to 2.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.22%, marking a year-over-year increase of 759600.0%. This contributed to the annual value of 28.05% for FY2024, which is 9106200.0% up from last year.
  • ImmunityBio's Return on Sales amounted to 2.1% in Q3 2025, which was up 119500.0% from 3.5% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Return on Sales registered a high of 2.1% during Q3 2025, and its lowest value of 7357.0% during Q1 2022.
  • In the last 5 years, ImmunityBio's Return on Sales had a median value of 579.0% in 2021 and averaged 1314.07%.
  • In the last 5 years, ImmunityBio's Return on Sales plummeted by -67780000bps in 2022 and then soared by 70331600bps in 2023.
  • Quarter analysis of 5 years shows ImmunityBio's Return on Sales stood at 234.75% in 2021, then plummeted by -532bps to 1483.92% in 2022, then dropped by -13bps to 1679.24% in 2023, then surged by 100bps to 7.84% in 2024, then soared by 73bps to 2.1% in 2025.
  • Its Return on Sales stands at 2.1% for Q3 2025, versus 3.5% for Q2 2025 and 7.85% for Q1 2025.